Clinical trial NCT04220658: Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers
Official title: The NAD+ Baseline Study: a Biomarker-based Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Epigenetics
Lead sponsor: Elysium Health
Sponsor class: INDUSTRY
Collaborators: name: Duke Clinical Research Institute
First posted: 2020-01-07
Enrollment: 170
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals between 25-80 years of age

Brief summary: This is a single center, prospective study to evaluate correlations between epigenetic aging (as measured via DNA methylation) and NAD+ levels in healthy volunteers.

Detailed description: This biomarker study consists of a single outpatient visit to the research unit. At this visit, eligibility will be assessed and biomarker samples (blood, saliva and urine) will be collected from subjects meeting eligibility criteria. Consenting subjects with clinically significant screening lab values may be excluded from the study after biomarker sample collection (i.e., clinical lab test results will become available after the biomarker sample collection). The prescribing of drugs to humans will not be part of this protocol.

Eligibility criteria: Inclusion Criteria:

1. Males or females between 25 - 80 (inclusive) years of age
2. Able and willing to provide written consent, follow instructions to complete study questionnaire(s) and assessments
3. Peripheral venous access sufficient for blood draw

Exclusion Criteria:

1. History of any significant chronic disease including renal, liver, endocrine, inflammatory, cardiovascular, gastro-intestinal, neurological, psychiatric, neoplastic, or metabolic disease, unless well controlled (defined as stable medication regimen) for at least 90 days prior to screening. Clinical significance of active disease will be assessed by the Qualified Investigator to determine eligibility.
2. Clinically significant, unstable or untreated medical disorders including recent myocardial ischemia or infarction, unstable angina, uncontrolled hypertension, AIDS, malignancy, epilepsy, and recent cerebrovascular disease that required a change in management or hospitalization within the last 90 days.
3. Subjects with or who have recently experienced a traumatic injury, infections or undergone major surgery at the discretion of the Qualified Investigator
4. Donation or receipt of blood products within 90 days.
5. Clinically significant vital sign or physical examination abnormality at the discretion of the Qualified Investigator.
6. Subjects with history of pellagra or niacin deficiency
7. Alcohol use \>2 standard alcoholic drinks per day within the past month
8. History of alcoholism or drug abuse within 1 year prior to screening
9. Use of medical marijuana or products containing cannabinoids in the 14 days prior to screening.
10. Use of lipid lowering agents (including fish oil) unless the dose has been stable for greater than 90 days prior to screening.
11. Use of natural health products containing nicotinamide riboside or niacin exceeding the RDA (16mg/day for males and 14mg/day for females) within 14 days prior to Screening. Potential participants will be asked to bring all supplements for evaluation at time of screening.
12. History of or current diagnosis of any cancer (except for successfully treated basal or squamous cell carcinoma of the skin) diagnosed less than 5 years prior to screening. Volunteers with cancer in full remission and more than 5 years after diagnosis are acceptable.
13. Has participated in any clinical trial with an investigational medicinal product within the past two months prior to the first dose in the current study
14. Clinically significant abnormal laboratory results at screening
15. Any other condition which in the Investigator's opinion may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant
16. Consumption of non-water beverage or food within approximately 8 hours of sample collection

Primary outcomes:
measure: Correlation between biological age, calculated using DNA isolated from blood, and circulating NAD+ levels
timeFrame: At baseline
Secondary outcomes:
measure: Correlations between biological age, calculated using DNA isolated from saliva, and circulating NAD+ levels
timeFrame: At baseline
measure: Correlations between biological age, calculated using DNA isolated from blood and saliva, and Omega-3 levels in blood
timeFrame: At baseline
Other outcomes:
measure: Age related markers in blood and urine
timeFrame: At baseline
Locations:
city: Durham
country: United States
facility: Duke Early Phase Clinical Research
state: North Carolina
Study officials:
affiliation: Duke Early Phase Clinical Research/DCRI
name: Jeffrey Guptill, MD
role: PRINCIPAL_INVESTIGATOR
References: